Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1995454

CC1c2c(ccc3c2c(Cl)cn3S(=O)(=O)c2ccccc2F)OCCN1C.O=C(O)C(F)(F)F

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39
PKM P14618 2/20 0.37
PKLR P30613 2/20 0.37
HTR6 P50406 8/20 0.35
RORC P51449 1/20 0.33
HTR2C P28335 1/20 0.33
KLK7 P49862 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1996662 0.93 PKM (0.41) ALDH1A1CYP1A2CYP2D6TSHRCYP2C19
Trifluoroacetic Acid SCHEMBL1996681 0.85 PKM (0.41) PKMPKLRHTR6RORCHTR2C
Trifluoroacetic Acid SCHEMBL1998907 0.85 ALDH1A1 (0.37) ALDH1A1CYP1A2CYP2D6TSHRCYP2C19
Trifluoroacetic Acid SCHEMBL1996223 0.83 CPT1A (0.40) ALDH1A1TSHRPKMRORC
SCHEMBL1995997 0.82 HTR6 (0.47) CYP2D6PKMPKLRHTR6HTR2C
SCHEMBL2001671 0.78 PKM (0.46) PKMPKLRHTR6HTR2CNPC1
SCHEMBL1998665 0.77 PKM (0.39) ALDH1A1CYP1A2CYP2D6TSHRCYP2C19
SCHEMBL1995457 0.75 PKM (0.37) ALDH1A1CYP1A2CYP2D6TSHRCYP2C19
Trifluoroacetic Acid SCHEMBL1997380 0.75 HTR6 (0.38) PKMPKLRHTR6HTR2C
SCHEMBL1999621 0.74 TSHR (0.45) ALDH1A1TSHRPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960374-B2 e.g. 2,5-methylene-9-(phenylsulfonyl)-1,2,3,4,5,9-hexahydro[1,5]oxazocino[3,2-e]indole; serotonin receptors antagonist or partial agonist; metabolic diseases, e.g. obesity, insulin resisitance, type 2 diabetes, eating disorders; antidepressant, anxiolytic agent; cosmetics PROXIMAGEN LIMITED (GB) 2011-06-14 US disclosed
EP-2091953-A1 8-SULFONYL-L, 3, 4, 8-TETRAHYDR0-2H- [1, 4]OXAZEPINO [6, 7-E]INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 RECEPTOR LIGANDS BIOVITRUM AB (publ) (SE) 2009-08-26 EP disclosed
US-20080176829-A1 Compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-07-24 US disclosed
WO-2008054288-A1 8-SULFONYL-L, 3, 4, 8-TETRAHYDR0-2H- [1, 4] OXAZEPINO [6, 7-E] INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 RECEPTOR LIGANDS BIOVITRUM AB (PUBL) (SE) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176829-A1 Compounds HTR6, HTR1B, HTR1A ALDH1A1 691/4885CYP1A2 257/4885CYP2D6 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.